您现在的位置：首页师资队伍教授

徐洁杰

发表时间：2021-05-28 阅读次数：2296次

徐洁杰，博士，教授，博士生导师。2002年获四川大学华西医学中心（原华西医科大学）医学学士学位，2005年获四川大学生命科学学院理学硕士学位，2010年获复旦大学上海医学院医学博士学位，之后在复旦大学基础医学院做生物学博士后研究，2012年博士后出站留校任教。先后入选全国优秀博士学位论文提名奖、教育部新世纪优秀人才支持计划、上海市青年科技启明星和复旦大学卓学人才计划。

近年来围绕肿瘤免疫方向，深入研究肿瘤免疫调控的细胞与分子机制。以第一作者和通讯作者在Gastroenterology、Gut、Hepatology、European Urology、Annals of Oncology、Nature Communications、JAMA Surgery、Annals of Surgery、Clinical Cancer Research、Cancer Research、Cell Death & Differentiation、Journal of Biological Chemistry、European Journal of Cancer、British Journal of Cancer、International Journal of Cancer、Oncoimmunology、Cancer Immunology Immonotherapy、Cell Death & Disease、Glycobiology等肿瘤学领域国际权威期刊发表SCI论文35篇，其中第一作者论文3篇，通讯作者论文32篇，ESI高被引论文1篇，影响因子10以上论文7篇，最高影响因子为19.233。

发现肿瘤细胞抑癌基因Notch1失活以及癌基因PAK1、CXCR4激活等肿瘤细胞促癌信号活化通过影响肿瘤细胞衰老样生长抑制和失巢凋亡等生物学行为促进肝癌发生发展的分子机制，阐明肿瘤相关巨噬细胞等肿瘤浸润免疫细胞功能表型变化在肿瘤细胞促癌信号诱导免疫逃逸形成过程中的关键作用及其细胞分子机制，这些发现对于认识肿瘤免疫逃逸形成机制具有重要意义，同时也为肿瘤免疫治疗提供了新的靶点。

多次受邀为Lancet、Lancet Oncology、Hepatology、Journal of the American Society of Nephrology、International Journal of Cancer、Molecular Cancer、Cancer Letters、Endocrine-Related Cancer、Cancer Immunology Immonotherapy、Journal of Hematology & Oncology、Cell Death & Disease等国际知名肿瘤学期刊审稿。

联系方式

联系地址：上海市东安路130号西7号楼 408室

电子邮箱：jjxufdu@fudan.edu.cn

主要研究方向

肿瘤免疫调控的细胞与分子机制

代表性论文列表 (* 为通讯作者)

1. Zeng H, Liu Z, Wang Z, Zhou Q, Qi Y, Chen Y, Chen L, Zhang P, Wang J, Chang Y, Bai Q, Xia Y, Wang Y, Liu L, Zhu Y, Dai B, Guo J, Xu L*, Zhang W*, Xu J*. Intratumoral IL22-producing cells define immunoevasive subtype muscle-invasive bladder cancer with poor prognosis and superior nivolumab responses. Int J Cancer. 2020; 146(2):542-552.(共同通讯作者，IF=4.982)

2. Lin C, He H, Liu H, Li R, Chen Y, Qi Y, Jiang Q, Chen L, Zhang P, Zhang H, Li H, Zhang W*, Sun Y*, Xu J*. Tumor-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer. Gut. 2019; 68(10):1764-1773. (共同通讯作者，IF=17.943)

3. Fu Q, Xu L, Wang Y, Jiang Q, Liu Z, Zhang J, Zhou Q, Zeng H, Tong S, Qi Y, Hu B, Fu H, Xie H, Zhou L, Chang Y, Zhu Y, Dai B*, Zhang W*, Xu J*. Tumor-associated macrophage-derived IL-23 interlinks kidney cancer glutamine addiction with immune evasion. Eur Urol. 2019; 75(5): 752-763. (共同通讯作者，IF=17.298)

4. WangJT, Li H, Zhang H, Chen YF, Cao YF, Li RC, Lin C, Wei YC, Xiang XN, Fang HJ, Zhang HY, Gu Y, Liu X, Zhou RJ, Liu H, He HY, Zhang WJ*, Shen ZB*, Qin J*, Xu JJ*. Intratumoral IL17-producing cells infiltration correlate with anti-tumor immune contexture and improved response to adjuvant chemotherapy in gastric cancer. Ann Oncol. 2019; 30(2): 266-273. (共同通讯作者，IF=14.196)

5. Wang J, Liu L, Bai Q, Ou C, Xiong Y, Qu Y, Wang Z, Xia Y, Guo J*, Xu J*. Tumor-infiltrating neutrophils predict therapeutic benefit of tyrosine kinase inhibitors in metastatic renal cell carcinoma. Oncoimmunology. 2019; 8(1): e1515611. (共同通讯作者，IF=5.333)

6. Qi Y, Chang Y, Wang Z, Chen L, Kong Y, Zhang P, Liu Z, Zhou Q, Chen Y, Wang J, Bai Q, Xia Y, Liu L, Zhu Y, Xu L, Dai B, Guo J, Wang Y*, Xu J*, Zhang W*. Tumor-associated macrophages expressing galectin-9 identify immunoevasive subtype muscle-invasive bladder cancer with poor prognosis but favorable adjuvant chemotherapeutic response. Cancer Immunol Immunother. 2019; 68(12):2067-2080. (共同通讯作者，IF=4.900)

7. Xiong Y, Liu L, Xia Y, Qi Y, Chen Y, Chen L, Zhang P, Kong Y, Qu Y, Wang Z, Lin Z, Chen X, Xiang Z, Wang J, Bai Q, Zhang W, Yang Y, Guo J*, Xu J*. Tumor infiltrating mast cells determine oncogenic HIF-2α-conferred immune evasion in clear cell renal cell carcinoma. Cancer Immunol Immunother. 2019; 68(5):731-741. (共同通讯作者，IF=4.900)

8. Jiang Q, Fu Q, Chang Y, Liu Z, Zhang J, Xu L, Zhu Y, Wang Y, Zhang W*, Xu J*. CD19(+) tumor-infiltrating B-cells prime CD4(+) T-cell immunity and predict platinum-based chemotherapy efficacy in muscle-invasive bladder cancer. Cancer Immunol Immunother. 2019; 68(1): 45-56. (共同通讯作者，IF=4.900)

9. Fu H, Zhu Y, Wang Y, Liu Z, Zhang J, Xie H, Fu Q, Dai B, Ye D*, Xu J*. Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle Invasive Bladder Cancer. Clin Cancer Res. 2018; 24(13): 3069–78. (共同通讯作者，IF=8.911)

10. Zhang H, Liu H, Shen Z, Lin C, Wang X, Qin J, Qin X, Xu J*, Sun Y*. Tumor infiltrating neutrophils is prognostic and predictive for postoperative adjuvant chemotherapy benefit in patients with gastric cancer. Ann Surg. 2018; 267(2): 311-318. (共同通讯作者，IF=9.476，ESI高被引论文)

11. Lin Z, Liu L, Xia Y, Chen X, Xiong Y, Qu Y, Wang J, Bai Q, Guo J*, Xu J*. Tumor infiltrating CD19+ B lymphocytes predict prognostic and therapeutic benefits in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors. Oncoimmunology. 2018; 7(10): e1477461. (共同通讯作者，IF=5.333)

12. Liu Z, Zhu Y, Xu L, Zhang J, Xie H, Fu H, Zhou Q, Chang Y, Dai B*, Xu J*. Tumor stroma-infiltrating mast cells predict prognosis and adjuvant chemotherapeutic benefits in patients with muscle invasive bladder cancer. Oncoimmunology. 2018; 7(9): e1474317. (共同通讯作者，IF=5.333)

13. Wu S, He H, Liu H, Cao Y, Li R, Zhang H, Li H, Shen Z*, Qin J*, Xu J*. C-C motif chemokine 22 predicts postoperative prognosis and adjuvant chemotherapeutic benefits in patients with stage II/III gastric cancer. Oncoimmunology. 2018; 7(6): e1433517. (共同通讯作者，IF=5.333)

14. Wei Y, Lin C, Li H, Xu Z, Wang J, Li R, Liu H, Zhang H, He H*, Xu J*. CXCL13 expression is prognostic and predictive for postoperative adjuvant chemotherapy benefit in patients with gastric cancer. Cancer Immunol Immunother. 2018; 67(2): 261-269. (共同通讯作者，IF=4.900)

15. Wang J, Liu L, Qu Y, Xi W, Xia Y, Bai Q, Xiong Y, Long Q, Xu J*, Guo J*. HLA class I expression predicts prognosis and therapeutic benefits from tyrosine kinase inhibitors in metastatic renal-cell carcinoma patients. Cancer Immunol Immunother. 2018; 67(1): 79-87. (共同通讯作者，IF=4.900)

16. Cao Y, Liu H, Li H, Lin C, Li R, Wu S, Zhang H, He H*, Zhang W*, Xu J*. Association of O6-Methylguanine-DNA Methyltransferase Protein Expression With Postoperative Prognosis and Adjuvant Chemotherapeutic Benefits Among Patients With Stage II or III Gastric Cancer. JAMA Surg. 2017; 152(11): e173120. (共同通讯作者，IF=10.668)

17. Liu Y, Liu H, Yang L, Wu Q, Liu W, Fu Q, Zhang W, Zhang H, Xu J*, Gu J*. Loss of N-acetylgalactosaminyltransferase-4 orchestrate oncogenic microRNA-9 in hepatocellular carcinoma. J Biol Chem. 2017; 292(8): 3186-200. (共同通讯作者，IF=4.106)

18. Zhu Y, Liu Z, Wang Y, Fu H, Wang Z, Xie H, Zhang J, Li G, Dai B, Xu J*, Ye D*. High CXC chemokine receptor 1 level represents an independent negative prognosticator in non-metastatic clear-cell renal cell carcinoma patients. Oncoimmunology. 2017; 6(11): e1359450. (共同通讯作者，IF=5.333)

19. Wang J, Lin C, Li H, Li R, Wu Y, Liu H, Zhang H, He H, Zhang W*, Xu J*. Tumor-infiltrating γδT cells predict prognosis and adjuvant chemotherapeutic benefits in patients with gastric cancer. Oncoimmunology. 2017; 6(11): e1353858. (共同通讯作者，IF=5.333)

20. Zhou L, Xu L, Chen L, Fu Q, Liu Z, Chang Y, Lin Z*, Xu J*. Tumor infiltrating neutrophils predict benefit from adjuvant chemotherapy in patients with muscle invasive bladder cancer. Oncoimmunology. 2017; 6(4): e1293211. (共同通讯作者，IF=5.333)

21. Liu H, Liu Y, Liu W, Zhang W, Xu J*. EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma. Nat Commun. 2015; 6: 8494. (通讯作者，IF= 11.878)

22. Zhang W, Liu H, Liu W, Liu Y, Xu J*. Polycomb-mediated loss of microRNA let-7c determines inflammatory macrophage polarization via PAK1-dependent NF-κB pathway. Cell Death Differ. 2015; 22(2): 287-97. (通讯作者，IF=8.086)

23. Liu W, Liu Y, Liu H, Zhang W, Fu Q, Xu J*, Gu J*. Tumor suppressive function of p21-activated kinase 6 in hepatocellular carcinoma. J Biol Chem. 2015; 290(47): 28489-501. (共同通讯作者，IF=4.106)

24. Wu Q, Liu HO, Liu YD, Liu WS, Pan D, Zhang WJ, Yang L, Fu Q, Xu JJ*, Gu JX*. Decreased Expression of Hnf4α/miR-122 Axis in Hepatitis B Virus-associated Hepatocellular Carcinoma Enhances Potential Oncogenic GALNT10 Activity. J Biol Chem. 2015; 290(2): 1170-85. (共同通讯作者，IF=4.106)

25. An H, Xu L, Chang Y, Zhu Y, Yang Y, Chen L, Lin Z*, Xu J*. CXC chemokine receptor 2 is associated with postoperative recurrence and survival of patients with non-metastatic clear-cell renal cell carcinoma. Eur J Cancer. 2015; 51(14): 1953-61. (共同通讯作者，IF=6.680)

26. Fu Q, Chang Y, An H, Fu H, Zhu Y, Xu L, Zhang W*, Xu J*. Prognostic Value of Interleukin-6 and Interleukin-6 Receptor in Organ-Confined Clear-Cell Renal Cell Carcinoma: A 5-Year Conditional Cancer-Specific Survival Analysis. Br J Cancer. 2015; 113(11): 1581-1589. (共同通讯作者，IF=5.416)

27. Chang Y, An H, Xu L, Zhu Y, Yang Y, Lin Z*, Xu J*. Systemic inflammation score predicts postoperative prognosis of patients with clear-cell renal cell carcinoma. Br J Cancer. 2015; 113(4): 626-33. (共同通讯作者，IF=5.416)

28. Zhu Y, Liu H, Xu L, An H, Liu W, Liu Y, Lin Z, Xu J*. p21-activated kinase 1 determines stem-like phenotype and sunitinib resistance via NF-κB/IL-6 activation in renal cell carcinoma. Cell Death Dis. 2015; 6: e1637. (通讯作者，IF=5.959)

29. Zhang H, Wang X, Xu J*,Sun Y*. Notch1 activation is a poor prognostic factor in patients with gastric cancer. Br J Cancer. 2014; 110(9): 2283-90. (共同通讯作者，IF=5.416)

30. An H, Xu L, Zhu Y, Lv T, Liu W, Liu Y, Liu H, Chen L*, Xu J*, Lin Z*. High C-X-C chemokine receptor 4 expression is an adverse prognostic factor in patients with clear-cell renal cell carcinoma. Br J Cancer. 2014; 110(9): 2261-8. (共同通讯作者，IF=5.416)

31. He H, Shen Z, Zhang H, Wang X, Tang Z, Xu J*, Sun Y*. Clinical significance of polypeptide N-acetylgalactosaminyl transferase-5 (GalNAc-T5) expression in patients with gastric cancer. Br J Cancer. 2014; 110(8): 2021-9. (共同通讯作者，IF=5.416)

32. Liu J, Liu H, Zhang W, Wu Q, Liu W, Liu Y, Pan D, Xu J*, Gu J. N-acetylglucosaminyltransferase V confers hepatoma cells with resistance to anoikis through EGFR/PAK1 activation. Glycobiology. 2013; 23(9): 1097-109. (通讯作者，IF=4.194)

33. Xu J, Liu H (co-first author), Chen L, Wang S, Zhou L, Yun X, Sun L, Wen Y*, Gu J*. Hepatitis B virus X protein confers resistance of hepatoma cells to anoikis by up-regulating and activating p21-activated kinase 1. Gastroenterology. 2012; 143(1): 199-212.e4. (并列第一作者，IF=19.233)

34. Liu H, Xu J (co-first author), Zhou L, Yun X, Chen L, Wang S, Sun L, Wen Y*, Gu J*. Hepatitis B virus large surface antigen promotes liver carcinogenesis by activating the Src/PI3K/Akt pathway. Cancer Res. 2011; 71(24): 7547-57. (并列第一作者，IF=8.378)

35. Xu J, Yun X, Jiang J, Wei Y, Wu Y, Zhang W, Liu Y, Wang W, Wen Y*, Gu J*. Hepatitis B virus X protein blunts senescence-like growth arrest of human hepatocellular carcinoma by reducing Notch1 cleavage. Hepatology. 2010; 52(1): 142-54. (第一作者，IF=14.971)